Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on endovascular robotics through its LIBERTY Endovascular Robotic System. The news around MBOT centers on the commercialization of this FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and the company’s progress in bringing it into routine clinical use.
Investors and clinicians following Microbot Medical can find updates on key commercial milestones, such as the limited market release of LIBERTY in selected high procedure volume regions in the U.S. and the company’s plans for a broader market release aligned with major medical conferences. News items also cover the first hospital adoption of LIBERTY for patient care at Emory University Hospital and the collaboration to build an Endovascular Robotics Program in interventional radiology.
Coverage of MBOT includes regulatory and clinical developments, including FDA 510(k) clearance for LIBERTY and reported data from the ACCESS PVI pivotal trial, where the company cites 100% robotic navigation success, a 92% reduction in radiation exposure and no adverse device events. Additional articles highlight Microbot Medical’s presence at professional meetings, its partnerships with third-party manufacturers and logistics providers, and its work on teleintervention and autonomous robotics collaborations.
Financial and corporate news for Microbot Medical features capital-raising activities through exercises of preferred investment options, as well as updates on its intellectual property portfolio, such as new patents in jurisdictions including Japan. For readers tracking MBOT, this news feed offers a focused view of how the company is advancing the LIBERTY System, expanding its commercial infrastructure and executing on its endovascular robotics strategy over time.
Microbot Medical has announced a partnership with Baptist Hospital of Miami to participate in its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System. This follows recent FDA approval to start the trial. Baptist Hospital is the second site to enroll, joining Brigham and Women's Hospital. The trial has received Institutional Review Board approval, and a Clinical Trial Agreement has been signed. Dr. Ripal Gandhi will be the principal investigator. The LIBERTY technology aims to revolutionize endovascular procedures, with significant interest from leading healthcare institutions.
Microbot Medical has partnered with Brigham and Women's Hospital (BWH) to conduct a pivotal human clinical trial for its LIBERTY® Endovascular Robotic Surgical System. This follows the FDA's approval to commence the trial. BWH has received multiple LIBERTY systems and completed the Site Initiation Visit, which included training for clinical staff. Dr. Dmitry Rabkin will lead the study at BWH. Microbot is also engaging other leading centers to participate in the trial.
Microbot Medical has announced that Brigham and Women’s Hospital (BWH) in Boston will be a site for its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System as part of its Investigational Device Exemption (IDE) application. Dr. Dmitry Rabkin has been appointed as the principal investigator at BWH. The site initiation visit has been completed, and BWH staff have been trained on the clinical study protocols. Additionally, a shipment of LIBERTY investigational units has been delivered to BWH. Microbot Medical is also in the process of enlisting other leading centers for the clinical trial.
Microbot Medical (NASDAQ: MBOT) announced the closing of a $2.35 million registered direct offering priced at-the-market under Nasdaq rules, selling 1,566,669 shares at $1.50 per share. Concurrently, the company issued unregistered Series F preferred investment options for up to 3,133,338 shares at $1.50 per share, exercisable for two years. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the net proceeds for the development and commercialization of the LIBERTY® Robotic System, expansion of its IP portfolio, and general corporate purposes.
Microbot Medical (Nasdaq: MBOT) has announced a registered direct offering for the purchase and sale of 1,566,669 shares at $1.50 per share, totaling approximately $2.35 million in gross proceeds. Concurrently, unregistered series F preferred investment options to purchase up to 3,133,338 shares at the same price will be issued in a private placement. The closing is expected around June 4, 2024, pending customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The net proceeds will fund the development and commercialization of the LIBERTY® Robotic System, other IP projects, and general corporate purposes.
Microbot Medical has received FDA approval to start its pivotal human clinical trial for the LIBERTY® Endovascular Robotic Surgical System.
The trial will be conducted in the U.S. and will complement preclinical data to support a future 510(k) submission. The company has signed a clinical trial service agreement with a leading academic medical center and is engaging additional centers.
In parallel, Microbot Medical is completing biocompatibility tests required for the IDE application. CEO Harel Gadot expressed confidence in the technology and commitment to achieving regulatory clearance and commercialization.
Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of the first phase of its collaboration with Corewell Health, showcasing the technical capabilities of its LIBERTY® Endovascular Robotic Surgical System. The partnership aims to explore remote endovascular procedures utilizing the LIBERTY System. Led by Dr. Ryan Madder, the collaboration has shown promising results in a pre-clinical study published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
Summary not available.
Summary not available.
Summary not available.